Reported Earnings • Aug 05
Second quarter 2026 earnings released: kr0.036 loss per share (vs kr0.30 loss in 2Q 2025) Second quarter 2026 results: kr0.036 loss per share (improved from kr0.30 loss in 2Q 2025). Net loss: kr17.6m (loss narrowed 17% from 2Q 2025). Aankondiging • Jul 02
Malin Lundberg to Leave Cell Impact AB as CFO and Remain with the Company Until 30 September 2026 Cell Impact AB announced that Malin Lundberg had decided to leave her position as CFO and would remain with the company until September 30, 2026. Malin Lundberg was appointed CFO in February 2024, having previously served as Business Controller since 2021. Responsibility for the company's accounting and financial reporting activities would be assumed internally. The company did not intend to appoint a successor immediately and would revisit the recruitment process once anticipated key orders had been secured. Aankondiging • Mar 21
Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026 Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15, by hantverket on sturegatan 15, stockholm Sweden Reported Earnings • Aug 24
Second quarter 2025 earnings released: kr0.03 loss per share (vs kr0.035 loss in 2Q 2024) Second quarter 2025 results: kr0.03 loss per share. Net loss: kr21.2m (loss widened 1.7% from 2Q 2024). Aankondiging • May 20
Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million. Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million.
Security Name: Series B Shares
Security Type: Common Stock
Securities Offered: 3,133,220,076
Price\Range: SEK 0.02
Transaction Features: Rights Offering Aankondiging • Apr 24
Cell Impact AB (Publ) Announces Board Changes Cell Impact AB (publ) at the annual general meeting held on 24 April 2025 Mats Boquist was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee. Aankondiging • Mar 21
Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025 Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15 konferens, & event on sturegatan 15, stockholm Sweden Board Change • Dec 30
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Aankondiging • Sep 10
Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024 The Board of Directors has appointed Daniel Vallin as the permanent CEO of Cell Impact. Daniel Vallin has been serving as interim CEO since January 1, 2024. Daniel Vallin, with extensive industrial experience from companies such as Scania CV AB, was recruited to Cell Impact as COO in 2021 and has been the interim CEO of Cell Impact since the beginning of 2024. Today, the board of directors of Cell Impact has appointed him as the permanent CEO with effect from October 1, 2024. Reported Earnings • Aug 25
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr24.0m (up 37% from 2Q 2023). Net loss: kr20.9m (loss narrowed 27% from 2Q 2023). Aankondiging • Aug 23
Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030 Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million.
For the year 2030, the company targets sales of more than SEK 600 million. Aankondiging • Jul 03
Cell Impact Adds Sealing as A New Part of Production Process Cell Impact AB (publ) continues to develop its production process to better meet customer demand. The latest addition to the company’s production process is the opportunity to seal bipolar flow plates through dispersion. Sealing is a critical part of the assembly of bipolar flow plates for fuel cells and electrolyzers. Dispensing is one of the most popular sealing solutions used in the industry today. Reported Earnings • May 15
First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023) First quarter 2024 results: kr0.04 loss per share (improved from kr0.40 loss in 1Q 2023). Revenue: kr6.10m (down 70% from 1Q 2023). Net loss: kr23.4m (loss narrowed 23% from 1Q 2023). Aankondiging • Apr 26
Cell Impact AB (Publ) Announces Board and Committee Changes Cell Impact AB (publ) announced that at the AGM held on 25 April 2024, elected Jan Pieters and Mats Boquist as board members for the period until the end of the next annual general meeting. Mats Franzén was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee. Reported Earnings • Feb 18
Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022) Full year 2023 results: kr1.11 loss per share. Revenue: kr47.7m (down 48% from FY 2022). Net loss: kr121.4m (loss widened 17% from FY 2022). New Risk • Jan 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.05m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (96% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Market cap is less than US$10m (€9.05m market cap, or US$9.82m). Recent Insider Transactions • Dec 29
Chief Executive Officer recently bought €4.5k worth of stock On the 20th of December, Pär Teike bought around 238k shares on-market at roughly €0.019 per share. This transaction increased Pär's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of €19k worth in shares. Aankondiging • Dec 20
Cell Impact AB (publ) Announces CEO Changes Cell Impact AB (publ) announced that Pär Teike, CEO since 2017, has decided to leave his role and Cell Impact. Daniel Vallin, Cell Impact's COO since 2021, is proposed to take over as acting CEO from January 1, 2024, until a decision is made regarding a permanent CEO of Cell Impact. Daniel Vallin, 46 years old, is a Master of Science in Industrial Engineering with extensive industrial experience from among others, Scania CV AB. New Risk • Dec 19
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 6x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (88% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€14.3m market cap, or US$15.7m). Aankondiging • Dec 13
Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFO Cell Impact AB (publ) announced that Stefan Axellie, has decided to leave his role and Cell Impact by spring 2024. The process of identifying a successor will start within short. Stefan Axellie will stay on in his role until spring 2024 during the recruitment of his successor. Reported Earnings • Nov 04
Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022) Third quarter 2023 results: kr0.33 loss per share (improved from kr0.38 loss in 3Q 2022). Revenue: kr9.19m (down 38% from 3Q 2022). Net loss: kr24.9m (loss narrowed 14% from 3Q 2022). Aankondiging • Oct 24
Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023 Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023. New Risk • Oct 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.06m (US$9.54m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr163m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€9.06m market cap, or US$9.54m). Aankondiging • Sep 29
Cell Impact AB (publ) Announces Anna Frick Will Leave the Board Cell Impact AB (publ) is announcing that board member Anna Frick will leave the board at her own request. Aankondiging • Aug 24
Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028 Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million. Aankondiging • Jul 04
Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product Development Cell Impact AB (publ) announced that it is created by forming very thin sheets of metal with high velocity, in a single stroke, to create complex patterns. Extreme precision is required for the finished flow plate to work. With this new measuring technology, there is unique capacity to measure up to one-twentieth of a single strand of hair. To secure the best possible conditions, the measuring facility is built as a separate entity within the factory in Karlskoga. The slightest vibrations affect the measurement result - as do changes in temperature. Therefore, there is no contact between the room and external walls and the temperature is kept at 20 degrees around the clock, with a permissible variation of 0.4 degrees. The measuring equipment is used to measure flow plates, forming tools and fixtures. The investment in new measurement technology is part of Phase II, Cell Impact's strategy to develop its offering and productivity, which aims to better satisfy the customers' development objectives. The instruments include Hexagon Global Blue 7.10.7, Hexagon Global Blue 12.22.10 and Leitz PMM Gold 7.7.5, and gives Cell Impact better opportunities to measure complex geometries quickly, accurately, and continuously. Reported Earnings • Feb 18
Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021) Full year 2022 results: kr1.38 loss per share (further deteriorated from kr1.35 loss in FY 2021). Revenue: kr92.1m (up 13% from FY 2021). Net loss: kr104.2m (loss widened 31% from FY 2021). Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Nov 05
Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021) Third quarter 2022 results: kr0.38 loss per share (further deteriorated from kr0.25 loss in 3Q 2021). Revenue: kr14.7m (down 47% from 3Q 2021). Net loss: kr28.9m (loss widened 97% from 3Q 2021). Reported Earnings • Aug 26
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr26.5m (up 27% from 2Q 2021). Net loss: kr22.2m (loss narrowed 6.6% from 2Q 2021). Aankondiging • May 26
Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC Cell Impact AB (publ) PUBL SHARE AK B (Sweden) will be deleted from Other OTC effective from May 26, 2022, due to CUSIP Suspended. Board Change • May 13
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. 
